晚期食管癌患者化疗前后检测CRP、VEGF、IL-6的临床价值  

Clinical value of CRP,VEGF and IL-6 in patients with advanced esophageal cancer before and after chemotherapy

作　　者：马晓 陈国荣[1] 李君艳[1] 杨慧林 MA Xiao;CHEN Guorong;LI Junyan;YANG Huilin(Department of Oncology 2,the Third Affiliated Hospital of Xinxiang Medical College,Xinxiang 453003)

机构地区：[1]新乡医学院第三附属医院肿瘤内二科,新乡453003

出　　处：《南通大学学报（医学版）》2021年第5期438-441,共4页Journal of Nantong University(Medical sciences)

基　　金：新乡市科技攻关项目(GG2019044)。

摘　　要：目的:探讨晚期食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)患者化疗前后C-反应蛋白(C-reactive protein,CRP)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、白细胞介素-6(interleukin-6,IL-6)水平检测的临床价值。方法:选取2017年9月—2020年2月在新乡医学院第三附属医院治疗的晚期ESCC患者58例。应用长春瑞滨联合顺铂方案(简称NP方案)化疗,2个周期化疗后行近期疗效评价,观察化疗不良反应,化疗前1周内及2个周期化疗结束后1周,分别检测CRP、VEGF、IL-6水平,对比不同疗效患者化疗前后三者的水平变化。结果:2个周期化疗后完全缓解(complete remission,CR)0例,部分缓解(partial remission,PR)23例,疾病稳定(stable disease,SD)24例,疾病进展(progressive disease,PD)11例;客观缓解率为39.66%,疾病控制率为81.03%。出现Ⅲ度白细胞减少1例,其余均为Ⅰ~Ⅱ度毒副反应。PR组患者化疗后CRP、VEGF和IL-6水平较化疗前均明显降低(均P<0.05);PD组患者化疗后CRP水平较化疗前明显升高(P<0.05),且PD组患者的化疗前IL-6水平明显高于PR组。结论:NP方案治疗晚期ESCC患者疗效较好,且不良反应易耐受;监测CRP、VEGF、IL-6对晚期ESCC患者疗效的评估与预测有一定的临床价值。Objective:To investigate the clinical value of C-reactive protein(CRP),vascular endothelial growth factor(VEGF)and interleukin-6(IL-6)levels in patients with advanced esophageal squamous cell carcinoma(ESCC)before and after chemotherapy.Methods:A total of 58 patients with advanced ESCC treated in the Third Affiliated Hospital of Xinxiang Medical College from September 2017 to February 2020 were selected.The vinorelbine combined with cisplatin regimen(NP regimen)was used for chemotherapy,and the short-term efficacy was evaluated after 2 cycles of chemotherapy,adverse reactions were observed.The levels of CRP,VEGF and IL-6 were measured 1 week before and after 2 cycles of chemotherapy,respectively.To compare the changes of the three levels before and after chemotherapy in patients with different efficacy.Results:After 2 cycles of chemotherapy,there were 0 cases of complete remission(CR),23 cases of progressive disease(PR),24 cases of stable disease(SD)and 11 cases of progressive disease(PD).The objective remission rate was 39.66%and the disease control rate was 81.03%.There was 1 case of leucopenia of degreeⅢ,and the others were all adverse reactions of degreeⅠ-Ⅱ.In the PR group,the levels of CRP,VEGF and IL-6 after chemotherapy were significantly lower than those before chemotherapy(P<0.05).The CRP level of patients in the PD group after chemotherapy was significantly higher than that before treatment(P<0.05),and the IL-6 level of patients in the PD group before chemotherapy was significantly higher than that of the PR group.Conclusion:NP regimen is effective and easy to tolerate in patients with advanced ESCC.Monitoring CRP,VEGF and IL-6 has certain clinical value in evaluating and predicting the efficacy of patients with advanced ESCC.

关 键 词：食管鳞状细胞癌 C-反应蛋白 血管内皮生长因子 白细胞介素-6 

分 类 号：R735.1[医药卫生—肿瘤]